#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Acquired thrombophilias as a cause of early pregnancy losses


Authors: M. Simonidesová 1;  J. Šimko 2;  M. Martišová 3;  K. Holomáň 4
Authors‘ workplace: Gynekologicko-pôrodnícke oddelenie NsP Považská Bystrica 1;  Gendiagnostica Bratislava s. r. o., Laboratórium molekulárnej biológie 2;  Klinika hematológie a transfuziológie SZU, LFUK a UNB Bratislava 3;  II. Gynekologicko-pôrodnícka klinika LFUK a UNB Bratislava 4
Published in: Transfuze Hematol. dnes,19, 2013, No. 3, p. 171-179.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Acquired thrombophilias are one of the causes of early miscarriages. The basis of these early pregnancy losses lies not in their thrombogenic potential, but in their ability to induce failure of implantation, placentation or embryonic development. Antiphospholipid syndrome is the most frequent acquired thrombophilia in pregnancy. Due to their pro-thrombotic potential, BCR/ABL negative myeloproliferative neoplasms, polycythemia vera and essential thrombocythemia, may be included in a wider group of acquired thrombophilic states. Their occurrence is rare in pregnancy, but it is relatively frequently associated with unfavourable outcomes of pregnancy and higher maternal complications. The authors offer a summary of basic knowledge relating to these nosological entities and an overview of literature regarding the relationship between acquired thrombophillic states and early pregnancy loss.

Key words:
acquired thrombophilia, antiphospholipid syndrome, polycythemia vera, essential thrombocythemia, miscarriage


Sources

1. Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006; 55 (5): 360-368.

2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2): 295-306.

3. Ulukus M, Arici A. Recurrent pregnancy losses. Current Women‘s Health Reviews 2007; 3: 217-227.

4. Doubek R, Petrovová D, Kalvodová J, Doubek M. Hematologické malignity v graviditě. Čes Gynek 2009; 74 (2): 138-143.

5. Burjanivová T, Marcinek J, Minárik G, et al. Naše skúsenosti s vyšetrovaním JAK2 mutácií pacientov s myeloproliferatívnymi ochoreniami z trepanobioptického materiálu kostnej drene. Česk Patol 2011; 47 (3): 115-117.

6. Campr V. Histologická diagnostika Ph-negativních myeloproliferativních neoplázií. Česk Patol 2011; 47 (3): 84-93.

7. Tóthová E, Kafková A. Súčasný pohľad na diagnostiku a liečbu esenciálnej trombocytémie (ET) a primárnej myelofibrózy (PMF). Onkológia 2012; 7 (6): 396-401.

8. Valera M-C, Parant O, Vayssiere C, Arnal J-F, Payrastre B. Essential thrombocythemia and pregnancy. Eur J Obstet Gynecol Reprod Biol 2011; 158 (2): 141–147.

9. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131 (2): 208-213.

10. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352 (17): 1779-1790.

11. Marcinek J, Plank L, Szépe P. Zmeny názvoslovia, klasifikácie a diagnostických kritérií myeloproliferatívnych ochorení podľa klasifikácie 2008. Transfuze Hematol dnes 2010; 16 (1): 35-41.

12. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365 (9464): 1054-1061.

13. Passamonti F. How I treat polycythemia vera. Blood 2012; 120 (2): 275-284.

14. Barbui T, Finazzi G. Myeloproliferative disease in pregnancy and other management issues. Hematology Am Soc Hematol Educ Program 2006: 246-252.

15. McNally RJ, Roman E, Cartwright RA. Leukemias and lymphomas: time trends in the UK. Cancer Causes Control 1999; 10 (1): 35-42.

16. Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. The managment and outcome of four pregnancies in women with idiopathic myelofibrosis. Br J Haematol 2008; 142 (3): 480-482.

17. Taylor UB, Bardeguez AD, Iglesias N, Gascon P. Idiopathic myelofibrosis in pregnancy: a case report and review of the literature. Am J Obstet Gynecol 1992; 167: 38-39.

18. Gotic M, Cvetkovic M, Bozanovic T, Cemerikic V. Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon. Srpski Archiv za Celokupno Lekarstvo 2001; 129: 304-308.

19. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoetic and lymphoid tissues. 4th ed. WHO Press, IARC, Lyon, 2008; 439.

20. Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica 2005; 90 (11): 1477-1483.

21. Hurley TJ, McKinnell JV, Irani MS, et al. Hematologic malignancies in pregnancy. Obstet Gynecol Clin North Am 2005; 32 (4): 595-614.

22. Fabris, F, Randi ML. Essential Thrombocythemia: past and present. Intern Emerg Med 2009; 4 (5): 381-388.

23. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001; 66 (3): 152-159.

24. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol 2009; 82 (5): 350-353.

25. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 2007; 110 (2): 485-489.

26. Kaandorp SP, Lauw MN, van der Schoot CE, et al. Prevalence of JAK2V617F mutation in women with unexplained recurrent miscarriage. J Thromb Haemost 2010; 8 (12): 2837-2839.

27. Khare M, Nelson-Piercy C. Acquired thrombophilias and pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17 (3): 491-507.

28. Rai R, Regan L. Recurrent miscarriage. Lancet 2006; 368: 601-611.

29. Tincani A, Balestrieri G, Danieli E, et al. Pregnancy complications of the antiphospholipid syndrome. Autoimmunity 2003; 36 (1): 27-32.

30. Lim W, Crowther MA. Antiphospholipid antibodies: a critical review of the literature. Curr Opin in Hematol 2007; 14 (5): 494-499.

31. Kvasnička J, Autoimunitní trombofilie v žilním systéme (antifosfolipidový syndrom). In: Kvasnička, J. Trombofilie a trombotické stavy v klinické praxi. 1. vyd. Praha, Grada Publishing a.s., 2003; 58-59.

32. Kubisz P, a kol. Antifosfolipidový syndróm (APS). In: Kubisz P, a kol. Hematológia a transfuziológia. 1. vyd. Bratislava, Praha, Grada Slovakia, spol. s r.o., 2006; 205-209.

33. Kupferminc MJ. Trombophilia and pregnancy. Reprod Biol and Endocrinol 2003; 1: 111.

34. Lazúr J, Antifosfolipidový syndróm. Interná med 2008; 8 (10): 527-531.

35. Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 2008; 77 (1): 51-56.

36. Subrt I, Ulcova-Gallova Z, Bibkova K, et al. Recurrent pregnancy loss and frequency of eight antiphospholipid antibodies and genetic thrombophilic factors in Czech women. Am J Reprod Immunol 2008; 59 (3), 193-200.

37. Bulíková A, Crha I. Antifosfolipidové protilátky a antifosfolipidový syndrom v porodnictví. Prakt Gyn 2004; 1: 6-10.

38. Matsubayashi H. Autoantibodies and coagulation in reproductive medicine. Reprod Med Biol 2009; 8 (4): 131-140.

39. Vila P, Hernández MC, López-Fernández MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72 (2): 209-213.

40. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20 (3): 231-236.

41. Shapiro GA. Antiphospholipid syndrome in obstetrics and gynecology. Semin Thromb Hemost 1994; 20 (1): 64-70.

42. MacLean MA, Cumming GP, McCall F, Walker ID, Walker JJ. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994; 101 (2): 103-106.

43. Rai RS, Regan L, Clifford K, et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10 (8): 2001-2005.

44. Kupferminc MJ, Roqué H. Je nosičství trombofilie příčinou časných spontánních potratů v prvním trimestru? Gynekologie po promoci 2004; V/VI: 55-58.

45. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10 (12): 3301-3304.

46. Regan L, Rai R. Thrombophilia and pregnancy loss. J Reprod Immunol 2002; 55 (1-2): 163-180.

47. Quenby S, Farquharson RG, Dawood F, Hughes AM, Topping J. Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum Reprod 2005; 20 (6): 1729-1732.

48. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. β2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 1, 104 (12): 3598-3602.

49. El-Gharib MN, Elhawary TM, Elshourbagy SH, Morad MA. Anti--annexin V antibodies in women with recurrent miscarriage. Clinical Medicine Insights: Reproductive Health 2010; 4: 29–33.

50. Matsubayashi H, Arai T, Izumi S, Sugi T, McIntyre JA, Makino T. Anti--annexin V antibodies in patients with early pregnancy loss or implantation failures. Fertil Steril 2001; 76 (4): 694-699.

51. Di Simone N, Castellani R, Caliandro D, Carusol A. Monoclonal anti-annexin V antibody inhibits trophoblast gonadotropins secretion and induces syncytiotrophoblast apoptosis. Biol Reprod 2001; 65 (6): 1766-1770.

52. Di Simone N, Di Nicuolo F, D’Ippolito S, et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010; 83 (2): 212-219.

53. Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci USA 1993; 90 (14): 6464-6467.

54. Tartakovsky B, Bermas BL, Sthoeger Z, Shearer GM, Mozes E. Defective maternal-fetal interaction in a murine autoimmune model. Hum Reprod 1996; 11 (11): 2408-2411.

55. Azem F, Geva E, Amit A, et al. High levels of anticardiolipin antibodies in patients with abnormal embryo morphology who attended an in vitro fertilization program. Am J Reprod Immunol 1998; 39 (3): 161-163.

56. Hajšmanová Z, Šlechtová J, Šigutová P, Ulčová-Gallová Z. Průběh těhotenství při dlouhodobém podávaní nízkomolekulárního heparinu pro opakované těhotenské ztráty. Čes Gynek 2008; 73 (5): 278-283.

57. Girardi G. Heparin treatment in pregnancy loss: Potential therapeutic benefits beyond anticoagulation. J Reprod Immunol 2005; 66 (1): 45-51.

58. Salmon JE. The use of LMWH in pregnancies at risk: new evidence or perception? J Thromb Haemost 2005; 3 (4): 783-785.

59. Girardi G, Redecha P, Salmon JE. A potential mechanism for therapeutics efficacy of heparin in antiphospholipid antibodies-induced pregnancy loss- inhibition of complement. Nat Med 2004; 10: 1222-1226.

60. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): 691-736.

61. Penka M, Binder T, Dulíček P. Antitrombotické zajištění těhotných žen podle rizika tromboembolické nemoci (TEN)- Doporučený postup. Česká Gynekologie 2013; 78 (Suppl): 34-36.

Labels
Haematology Internal medicine Clinical oncology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#